| Chemical Information | |
| Antiviral agent ID | DrugRepV_6359 | |
| Antiviral agent name | (2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide | |
| IUPAC Name | (2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide |  |
| SMILES (isomeric) | CCCC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C1=CC=C(\C=C2/SC(=O)N(CCCC)C2=O)C=C1)C(N)=O | |
| Molecular Formula | C33H51N9O6S | |
| Molecular Weight (g/mol) | 701.89 | |
| InChl | InChI=1/C33H51N9O6S/c1-3-5-10-23(27(35)43)39-29(45)24(11-7-8-17-34)41-30(46)25(12-9-18-38-32(36)37)40-28(44)22-15-13-21(14-16-22)20-26-31(47)42(19-6-4-2)33(48)49-26/h13-16,20,23-25H,3-12,17-19,34H2,1-2H3,(H2,35,43)(H,39,45)(H,40,44)(H,41,46)(H4,36,37,38)/b26-20-/t23-,24-,25-/s2 | |
| Structural Information | |
 |
|
| Clinical Information | |
| Biological Information | |
|
Secondary Indication | Dengue virus (DENV) 2 NA |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Drug concentration) | 3.5 ± 0.1 μM
| |
|
Secondary Indication (Cell based assay) | Protease Assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
|
Reference | Nitsche C, Schreier VN, Behnam MA, Kumar A, Bartenschlager R, Klein CD..Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture..J Med Chem. 2013 Nov 14;56(21):8389-403. doi: 10.1021/jm400828u. Epub 2013 Oct 22. PMID:24083834
|  |
|
Comment | The most promising in vitro affinities were observed for thiazolidinedione-based peptide hybrids containing hydrophobic groups with Ki values between 1.5 and 1.8 μM and competitive inhibition mechanisms. Rhodanine-capped peptide hybrids with hydrophobic substituents have, in correlation with their membrane permeability, a more pronounced antiviral activity in cell culture than the thiazolidinediones.
| |